Cartesian Therapeutics' lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b. Find ...
Zacks Investment Research on MSN
Cartesian Therapeutics, Inc. (RNAC) soars 10.3%: Is further upside left in the stock?
Cartesian Therapeutics, Inc. (RNAC) shares ended the last trading session 10.3% higher at $7.04. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
Special edition of Globe Magazine honors the best employers in Massachusetts BOSTON, MA, UNITED STATES, January 14, 2026 /EINPresswire.com/ — Cartesian has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results